Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity.
- DOI
- 10.1016/j.ymthe.2026.09.008
- Published
- 2026 Sep 10
- Container
- Molecular therapy : the journal of the American Society of Gene Therapy
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ymthe.2026.09.008,
title = {Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity.},
author = {Diby L and Malinge P and Moine V and Nouveau L and Chatel L and Masternak K and Shang L and Ferlin W and Fischer N and Cragg MS and Pittet M and Buatois V and Hatterer E},
year = {2026},
journal = {Molecular therapy : the journal of the American Society of Gene Therapy},
doi = {10.1016/j.ymthe.2026.09.008},
url = {https://doi.org/10.1016/j.ymthe.2026.09.008}
}RIS
TY - JOUR TI - Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity. AU - Diby L AU - Malinge P AU - Moine V AU - Nouveau L AU - Chatel L AU - Masternak K AU - Shang L AU - Ferlin W AU - Fischer N AU - Cragg MS AU - Pittet M AU - Buatois V AU - Hatterer E PY - 2026 JO - Molecular therapy : the journal of the American Society of Gene Therapy DO - 10.1016/j.ymthe.2026.09.008 UR - https://doi.org/10.1016/j.ymthe.2026.09.008 ER -
APA
L, D., P, M., V, M., L, N., L, C., K, M., L, S., W, F., N, F., MS, C., M, P., V, B., & E, H. (2026). Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity.. Molecular therapy : the journal of the American Society of Gene Therapy. https://doi.org/10.1016/j.ymthe.2026.09.008
Source records
- pubmed · retrieved 2026-09-25T15:40:21.088Z
- europe-pmc · retrieved 2026-09-25T15:40:21.110Z